Plasticell announces grant of fundamental CombiCult patents in U.S. and Japan

Monday, February 13, 2012 02:57 PM

Patents for CombiCult, combinatorial cell culture platform technology, have been granted in the U.S. and Japan, according to Plasticell, a biotechnology company specializing in high throughput technologies for directed stem cell differentiation.

CombiCult breaks the bottleneck in stem cell R&D programs—the discovery of optimized stem cell differentiation protocols. CombiCult also allows scientists to develop custom cell culture media (e.g. GMP compatible stem cell expansion media for cell therapy), create high value cell lines for toxicity testing in the pharmaceutical, cosmetic and nutrition industries, and to increase yield and decrease cost of bioprocess manufacturing.

“Plasticell's proprietary technology breaks the major bottleneck in current stem cell research,” commented Sir Martin Evans FRS, a founding member of Plasticell’s scientific advisory board and recipient of the Nobel prize for the isolation of embryonic stem cells. “Having followed CombiCult's development for almost a decade, I am delighted that the importance of this revolutionary technology is now being recognized through multiple industry awards and patents.”

Patents covering CombiCult have now been issued in the U.S., Europe, Japan, Australia and Singapore.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs